BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10557063)

  • 21. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
    Kaufmann SH
    Cancer Res; 1991 Feb; 51(4):1129-36. PubMed ID: 1705167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
    Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
    Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
    Grabowski DR; Holmes KA; Aoyama M; Ye Y; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Mol Pharmacol; 1999 Dec; 56(6):1340-5. PubMed ID: 10570063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
    Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
    Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.
    Koo HM; Gray-Goodrich M; Kohlhagen G; McWilliams MJ; Jeffers M; Vaigro-Wolff A; Alvord WG; Monks A; Paull KD; Pommier Y; Vande Woude GF
    J Natl Cancer Inst; 1999 Feb; 91(3):236-44. PubMed ID: 10037101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells.
    Minderman H; Wrzosek C; Cao S; Utsugi T; Kobunai T; Yamada Y; Rustum YM
    Cancer Chemother Pharmacol; 2000; 45(1):78-84. PubMed ID: 10647506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced expression of DNA topoisomerase II by recombinant human granulocyte colony-stimulating factor in human leukemia cells.
    Towatari M; Ito Y; Morishita Y; Tanimoto M; Kawashima K; Morishima Y; Andoh T; Saito H
    Cancer Res; 1990 Nov; 50(22):7198-202. PubMed ID: 1699657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
    Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerase II is nonfunctional in polyamine-depleted cells.
    Alm K; Berntsson P; Oredsson SM
    J Cell Biochem; 1999 Oct; 75(1):46-55. PubMed ID: 10462703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines].
    Matsumoto Y; Takano H; Nagao S; Iglesias A; Fojo T
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2265-9. PubMed ID: 9422071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
    Ellis AL; Nowak B; Plunkett W; Zwelling LA
    Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability.
    Kong XB; Rubin L; Chen LI; Ciszewska G; Watanabe KA; Tong WP; Sirotnak FM; Chou TC
    Mol Pharmacol; 1992 Feb; 41(2):237-44. PubMed ID: 1311406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.
    Jensen PB; Jensen PS; Demant EJ; Friche E; Sørensen BS; Sehested M; Wassermann K; Vindeløv L; Westergaard O; Hansen HH
    Cancer Res; 1991 Oct; 51(19):5093-9. PubMed ID: 1655244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line.
    Towatari M; Adachi K; Marunouchi T; Saito H
    Br J Haematol; 1998 Jun; 101(3):548-51. PubMed ID: 9633900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
    Kumar A; Ehrenshaft M; Tokar EJ; Mason RP; Sinha BK
    Biochim Biophys Acta; 2016 Jul; 1860(7):1519-27. PubMed ID: 27095671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus.
    Stanulla M; Wang J; Chervinsky DS; Aplan PD
    Leukemia; 1997 Apr; 11(4):490-6. PubMed ID: 9096688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
    Beere HM; Chresta CM; Hickman JA
    Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinoic acid and phorbol ester induced hyperphosphorylation of topoisomerase II-alpha is an early event in HL-60 human leukaemia cell differentiation: effect on topoisomerase activity and etoposide sensitivity.
    Chresta CM; Hall BF; Francis GE
    Leukemia; 1995 Aug; 9(8):1373-81. PubMed ID: 7643627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents.
    Perrin D; van Hille B; Hill BT
    Biochem Pharmacol; 1998 Aug; 56(4):503-7. PubMed ID: 9763227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.